Drug intelligence / Profile preview

WS-1707

Development stage: Preclinical
Lead developer: Academia Sinica
Modality: Small Molecules
Administration: Intravenous

Overview

WS-1707 is a novel, water-soluble nitrogen mustard (N-mustard)-benzene conjugate bearing a urea linker and a N,N-dimethylaminoethylcarboxamide hydrochloride side chain. Developed by Academia Sinica in collaboration with Memorial Sloan Kettering Cancer Center, WS-1707 acts as a DNA alkylating agent that induces DNA cross-linking. In preclinical studies, the compound demonstrated potent in vitro cytotoxicity and in vivo antitumor efficacy against various human tumor xenografts, including breast carcinoma (MX-1), prostate adenocarcinoma (PC-3, HL2), and colon cancer (HCT-116), with little to no cross-resistance to paclitaxel or vinblastine.

Other names: WS 1707WS1707WS-1707

Targets

DNA

Beyond the preview

Go deeper on WS-1707.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WS-1707.

Explore the full profile